From: Fred Crow, Head of Regulatory Affairs.
To: Regulatory Affairs staff, especially medical writers.
Re: Recent audit, readability, and warnings.
Dear RA staff,
I just wanted to give you a brief update on the self-inspection conducted last week by QA. Most of the results were very positive. It seems our documentation is of a high standard, especially with respect to completeness and technical details. However, in tearms of readability, we can still make some improvements in future patient information leaflets. We need to remember that not only healthcare professionals read these PILs, but also patients.
In addition, I have noticed something which, I think, some of you can improve on. It has to do with drug warnings. Yes, we do need to let patients know of any possible side effects. But, no, it is not necessary to alarm them unnecessarily. In other words, in future when describing possible side effects for products in the pipeline, we will need to differentiate more clearly between frequent and rare risk. In the case of the latter, we will need to be less direct in order to increase patient compliance.
Let’s talk about these two points at our department meeting on Friday. I will also be asking Wendy, our senior medical writer, to coach junior staff members.
Best regards
Fred
đang được dịch, vui lòng đợi..
![](//viimg.ilovetranslation.com/pic/loading_3.gif?v=b9814dd30c1d7c59_8619)